var data={"title":"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/contributors\" class=\"contributor contributor_credentials\">C Michael Gibson, MS, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/contributors\" class=\"contributor contributor_credentials\">Joseph P Carrozza, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/contributors\" class=\"contributor contributor_credentials\">Roger J Laham, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/contributors\" class=\"contributor contributor_credentials\">Donald Cutlip, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/contributors\" class=\"contributor contributor_credentials\">Gordon M Saperia, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 11, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary percutaneous coronary intervention (PCI), if performed in a timely fashion, is the reperfusion therapy of choice in patients who are having an acute ST elevation myocardial infarction (STEMI) or an MI with new or presumably new left bundle branch block or a true posterior MI. The clinical trials that support this conclusion, and which have generally compared PCI with fibrinolysis, will be reviewed here. The discussion of the circumstances in which fibrinolysis may be either a reasonable alternative to PCI or even preferred is found elsewhere. (See <a href=\"topic.htm?path=acute-st-elevation-myocardial-infarction-selecting-a-reperfusion-strategy\" class=\"medical medical_review\">&quot;Acute ST elevation myocardial infarction: Selecting a reperfusion strategy&quot;</a>.)</p><p>Issues related to the performance of primary PCI, such as the optimal time to intervention and adjunctive therapies, the importance of hospital and operator volume, the role of PCI after fibrinolysis (eg, rescue PCI or facilitated or adjunctive PCI), and the role of PCI in non-ST elevation acute coronary syndromes are discussed separately. (See <a href=\"topic.htm?path=primary-percutaneous-coronary-intervention-in-acute-st-elevation-myocardial-infarction-determinants-of-outcome\" class=\"medical medical_review\">&quot;Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome&quot;</a> and <a href=\"topic.htm?path=percutaneous-coronary-intervention-after-fibrinolysis-for-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction&quot;</a> and <a href=\"topic.htm?path=coronary-angiography-and-revascularization-for-unstable-angina-or-non-st-elevation-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Coronary angiography and revascularization for unstable angina or non-ST elevation acute myocardial infarction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">LIMITATIONS OF FIBRINOLYSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the primary role of thrombus in the genesis of acute coronary occlusion, the introduction of fibrinolytic therapy was a major advance in the treatment of acute ST elevation myocardial infarction (STEMI). The net effect in major fibrinolytic trials was an approximate 30 percent reduction in the 7 to 10 percent short-term mortality. (See <a href=\"topic.htm?path=characteristics-of-fibrinolytic-thrombolytic-agents-and-clinical-trials-in-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction&quot;</a>.)</p><p>Despite the clear benefits of fibrinolytic therapy compared with no reperfusion and its ease of use, there are issues of both efficacy and safety that limit its use. The following limitations provided part of the impetus for primary percutaneous coronary intervention (PCI):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The benefit of fibrinolysis is greatest when therapy is given within the first four hours after the onset of symptoms, particularly within the first <strong>70 minutes</strong> as the resistance of cross-linked fibrin to fibrinolysis is time-dependent (<a href=\"image.htm?imageKey=CARD%2F53374\" class=\"graphic graphic_figure graphicRef53374 \">figure 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Any longer delay decreases the amount of myocardial salvage and functional benefit. The absolute mortality benefit compared to placebo at five weeks is approximately 3 percent for those presenting within six hours from symptom onset, 2 percent for those presenting within 7 to 12 hours, and a nonsignificant 1 percent for those presenting within 13 to 18 hours [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/3\" class=\"abstract_t\">3</a>]. Unfortunately, many patients present to the hospital more than six hours after the onset of symptoms. (See <a href=\"topic.htm?path=fibrinolysis-for-acute-st-elevation-myocardial-infarction-initiation-of-therapy#H69239847\" class=\"medical medical_review\">&quot;Fibrinolysis for acute ST elevation myocardial infarction: Initiation of therapy&quot;, section on 'Timing'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although patency, defined as some antegrade flow through the site of obstruction, is restored in up to 87 percent of infarct-related arteries, normalization of blood flow (as assessed by the TIMI flow grade) occurs in only 50 to 60 percent [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/4-6\" class=\"abstract_t\">4-6</a>]. The clinical benefits of fibrinolytic therapy correlate only with the restoration of normal (TIMI grade 3) flow (<a href=\"image.htm?imageKey=CARD%2F51941\" class=\"graphic graphic_table graphicRef51941 \">table 1</a> and <a href=\"image.htm?imageKey=CARD%2F75629\" class=\"graphic graphic_figure graphicRef75629 \">figure 2</a> and <a href=\"image.htm?imageKey=CARD%2F70952\" class=\"graphic graphic_figure graphicRef70952 \">figure 3</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/4,7-11\" class=\"abstract_t\">4,7-11</a>]. In contrast, TIMI grade 3 flow is achieved in 93 to 96 percent of patients who undergo primary PCI [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/12,13\" class=\"abstract_t\">12,13</a>]. (See <a href=\"topic.htm?path=fibrinolytic-thrombolytic-agents-in-acute-st-elevation-myocardial-infarction-markers-of-efficacy#H3\" class=\"medical medical_review\">&quot;Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy&quot;, section on 'TIMI flow grade'</a>.) <br/><br/>Attainment of TIMI 3 flow is much more common with primary PCI: 93 to 96 percent in the PAMI and CADILLAC trials of more than 5400 patients [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After apparently successful fibrinolysis, evidence of early recurrence of ischemia (pain or ST segment shifts) has been observed in 20 to 30 percent of patients [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/14,15\" class=\"abstract_t\">14,15</a>], with frank fibrinolytic coronary reocclusion in 5 to 15 percent [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/5,16,17\" class=\"abstract_t\">5,16,17</a>], and reinfarction in 3 to 5 percent [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/18-20\" class=\"abstract_t\">18-20</a>]. Reinfarction is associated with higher rates of in-hospital, short-term, and long-term mortality [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/18,19\" class=\"abstract_t\">18,19</a>]; PCI is the preferred therapy [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=management-of-failed-fibrinolysis-thrombolysis-or-threatened-reocclusion-in-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Major hemorrhagic complications occur in 2 to 3 percent. The most serious is intracerebral hemorrhage, which occurs in as many as 1 percent overall [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/3,21,22\" class=\"abstract_t\">3,21,22</a>], 1.4 percent of older adults [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/23\" class=\"abstract_t\">23</a>], and over 4 percent in patients with multiple risk factors (<a href=\"image.htm?imageKey=CARD%2F62946\" class=\"graphic graphic_table graphicRef62946 \">table 2</a>). (See <a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Overview of the acute management of ST-elevation myocardial infarction&quot;</a> and <a href=\"topic.htm?path=fibrinolysis-for-acute-st-elevation-myocardial-infarction-initiation-of-therapy#H69243091\" class=\"medical medical_review\">&quot;Fibrinolysis for acute ST elevation myocardial infarction: Initiation of therapy&quot;, section on 'Stroke'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As many as 20 to 30 percent of patients presenting with an acute STEMI, particularly older adults, are not candidates for fibrinolytic therapy because of contraindications such as active internal bleeding, a recent stroke, or hypertension (<a href=\"image.htm?imageKey=CARD%2F68784\" class=\"graphic graphic_table graphicRef68784 \">table 3</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/24\" class=\"abstract_t\">24</a>]. (See <a href=\"topic.htm?path=primary-percutaneous-coronary-intervention-in-acute-st-elevation-myocardial-infarction-determinants-of-outcome\" class=\"medical medical_review\">&quot;Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome&quot;</a> and <a href=\"topic.htm?path=fibrinolysis-for-acute-st-elevation-myocardial-infarction-initiation-of-therapy#H1171216482\" class=\"medical medical_review\">&quot;Fibrinolysis for acute ST elevation myocardial infarction: Initiation of therapy&quot;, section on 'Contraindications'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Efficacy of fibrinolytic therapy has not been demonstrated in patients in cardiogenic shock (unless coronary perfusion pressure is increased with an Intraaortic balloon pump [IABP]) or those with prior coronary artery bypass surgery (CABG). (See <a href=\"topic.htm?path=prognosis-and-treatment-of-cardiogenic-shock-complicating-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fibrinolytic therapy does not necessarily involve early angiography, the findings of which may change treatment. In a report from the PAMI trial, 10 percent of patients who underwent angiography were considered inappropriate candidates for PCI due, in one-half of cases, to lack of residual stenosis that presumably reflected spontaneous clot lysis [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/25\" class=\"abstract_t\">25</a>]. Other patients have findings, such as severe three-vessel or left main coronary disease, or anatomic features unfavorable for PCI, that lead to a recommendation for surgical revascularization. Many experts now recommend routine angiography after fibrinolysis for those patients who have not had it performed for evidence of ongoing or recurrent ischemia.</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PRIMARY PCI VERSUS FIBRINOLYTIC TRIALS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Three types of trials of primary percutaneous coronary intervention (PCI) in ST elevation myocardial infarction (STEMI) have been performed: primary PCI with percutaneous transluminal coronary angioplasty compared to fibrinolysis; primary PCI with stenting compared to fibrinolysis; and primary PCI with stenting compared to primary PCI with balloon angioplasty.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Primary PCI with balloon angioplasty versus fibrinolysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The early trials comparing primary PCI with balloon angioplasty to fibrinolysis showed a significant reduction in mortality with the former [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/25,26\" class=\"abstract_t\">25,26</a>]. However, these trials are of limited utility to current practice for the following reasons: stenting is performed in almost all patients who undergo PCI; current generation fibrinolytic agents were not used in many of the trials; and anticoagulation and antiplatelet protocols differed significantly from contemporary practice.</p><p>Most of the important studies were included in a 1997 meta-analysis of 10 randomized trials which included 2606 patients randomly assigned to primary PCI with balloon angioplasty or fibrinolysis [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/27\" class=\"abstract_t\">27</a>]. The former was associated with the following benefits:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A significantly lower mortality at 30 days or less (4.4 versus 6.5 percent, odds ratio 0.66, 95% CI 0.46-0.94); the effect was similar among the different fibrinolytic regimens used.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A significantly lower rate of death or nonfatal reinfarction (7.2 versus 11.9 percent, odds ratio 0.58, 95% CI 0.44-0.76).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A lower rate of total stroke (0.7 versus 2.0 percent) and hemorrhagic stroke (0.1 versus 1.1 percent).</p><p/><p>The Primary Angioplasty in Myocardial Infarction trial (PAMI), published after the meta-analysis, randomly assigned 395 patients presenting with an acute MI within 12 hours of symptom onset to primary PCI with balloon angioplasty or 100 mg of intravenous recombinant tissue-type plasminogen activator (<a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a>) [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/25\" class=\"abstract_t\">25</a>]. Benefits, similar to those in the meta-analysis, were found with primary PCI with balloon angioplasty [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/25,28,29\" class=\"abstract_t\">25,28,29</a>]. An important observation in PAMI was that high-risk groups (age &gt;70, anterior MI, heart rate &gt;100 on admission) derived the greatest benefit.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Primary PCI with stenting versus primary PCI with balloon angioplasty</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical efficacy of primary PCI with balloon angioplasty in acute STEMI is limited by the risks of early reocclusion and late restenosis, providing the rationale for the use of intracoronary stents. Initial nonrandomized studies suggesting that primary stenting was more effective than primary percutaneous transluminal coronary angioplasty (PTCA) [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/30-32\" class=\"abstract_t\">30-32</a>] were followed by randomized trials [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/13,33-35\" class=\"abstract_t\">13,33-35</a>]. Subsequent randomized trials, including Stent PAMI and CADILLAC, confirmed the greater efficacy of stenting compared with balloon angioplasty for patients with STEMI [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/13,33\" class=\"abstract_t\">13,33</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Meta-analysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A 2005 meta-analysis evaluated nine randomized trials with a total of 4433 patients [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/36\" class=\"abstract_t\">36</a>]. Stenting (predominantly with bare metal stents), compared to balloon angioplasty, was associated with significant reductions in reinfarction (odds ratio [OR] 0.52, 95% CI 0.31-0.87 at 30 days, and OR 0.67, 95% CI 0.45-0.98 at one year) and target vessel revascularization (OR 0.45, 95% CI 0.34-0.60 at 30 days, and OR 0.47, 95% CI 0.38-0.57 at one year). There was no significant difference in mortality (OR 1.06 at one year).</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Primary PCI with stenting versus fibrinolysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several randomized trials (DANAMI-2, PRAGUE-2, AIR PAMI, STAT, STOPAMI-1, and STOPAMI-2) have demonstrated a better outcome with primary PCI with stenting compared to fibrinolysis [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/37-45\" class=\"abstract_t\">37-45</a>]. In the two largest trials, DANAMI-2 and PRAGUE-2, most of the patients presented to hospitals without PCI facilities. Bare-metal stents were used in these trials.</p><p>The DANAMI-2 trial randomly assigned 1572 patients to front-loaded <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a> or to primary PCI with stenting (93 percent with stenting) [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/37\" class=\"abstract_t\">37</a>]. The majority of patients were initially evaluated in referral hospitals, and then transferred to a PCI center if randomized to primary PCI. Inclusion criteria included STEMI, duration of symptoms less than 12 hours (median 105 minutes), and ability to complete transfer to a PCI center within three hours of randomization. For those patients enrolled in referral centers, the median time between randomization and arrival in the catheterization laboratory was 67 minutes, with 96 percent arriving within 120 minutes.</p><p>The study was discontinued prematurely because of a significant reduction in the primary end point of mortality, reinfarction, or stroke at 30 days with primary PCI (8.0 versus 13.7 percent). The mortality benefit was noted only in the subgroup of high-risk patients with a TIMI risk score &ge;5 at presentation [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/38\" class=\"abstract_t\">38</a>]. The benefit remained significant at three years (19.5 versus 25.2 percent) and was primarily due to less clinical reinfarction (8.9 versus 12.3 percent) [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/39\" class=\"abstract_t\">39</a>]. At median follow-up of 7.8 years, the combined end point of death or reinfarction was significantly lower in the primary PCI group (34.8 versus 41.3 percent), attributable to a significantly lower reinfarction rate (11.7 versus 18.5 percent) [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/46\" class=\"abstract_t\">46</a>]. (See <a href=\"#H8\" class=\"local\">'High- versus low-risk patients'</a> below.)</p><p>Potential limitations to DANAMI-2 included the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Repeat fibrinolysis in the <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a> group as opposed to rescue PCI, which is the preferred approach. (See <a href=\"topic.htm?path=management-of-failed-fibrinolysis-thrombolysis-or-threatened-reocclusion-in-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Absence of protocol mandated <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> in all patients and glycoprotein <span class=\"nowrap\">IIb/IIIa</span> inhibitors in most patients undergoing primary PCI, both of which are recommended in most major guidelines. (See <a href=\"topic.htm?path=antiplatelet-agents-in-acute-st-elevation-myocardial-infarction#H36\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute ST elevation myocardial infarction&quot;, section on 'Summary and recommendations'</a>.)</p><p/><p>The PRAGUE-2 trial randomly assigned 850 patients with an STEMI who had had symptoms for less than 12 hours to immediate fibrinolysis with streptokinase at the presenting community hospital or transfer to a PCI center [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/40\" class=\"abstract_t\">40</a>]. Primary PCI was associated with a nonsignificant trend toward lower mortality at 30 days (6.8 versus 10.0 percent with fibrinolysis). At five years, the cumulative incidence of the composite end point (death from any cause, recurrent infarction, stroke, or revascularization) was significantly lower in the primary PCI group (40 versus 50 percent), driven principally by a lower rate of recurrent infarction [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/41\" class=\"abstract_t\">41</a>].</p><p>The potential benefit of using drug eluting stents instead of bare-metal stents in patients with STEMI has been evaluated in multiple randomized trials. This issue is discussed separately. (See <a href=\"topic.htm?path=primary-percutaneous-coronary-intervention-in-acute-st-elevation-myocardial-infarction-periprocedural-management#H24756048\" class=\"medical medical_review\">&quot;Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management&quot;, section on 'Selection of stent type'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">High- versus low-risk patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A later analysis from the DANAMI-2 trial cited above stratified patients according to the TIMI risk score for STEMI in an attempt to assess whether all patients with STEMI benefit from primary PCI [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/38\" class=\"abstract_t\">38</a>]. The score is the arithmetic sum of eight independent predictors of mortality available at presentation; there is a continuous relationship between mortality and score, which has been prospectively validated (<a href=\"image.htm?imageKey=CARD%2F78134\" class=\"graphic graphic_figure graphicRef78134 \">figure 4</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=risk-stratification-after-acute-st-elevation-myocardial-infarction#H3\" class=\"medical medical_review\">&quot;Risk stratification after acute ST-elevation myocardial infarction&quot;, section on 'TIMI risk score'</a>.)</p><p>In a three-year follow-up from the DANAMI-2 cohort, primary PCI was associated with a significant reduction in mortality at three years compared to fibrinolysis in high-risk patients with a TIMI risk score &ge;5 (25.3 versus 36.2 percent) [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/38\" class=\"abstract_t\">38</a>]. In contrast, there was no mortality benefit from primary PCI in the 74 percent of patients who were at low risk with a score of 0 to 4 (8.0 versus 5.6 percent), and only a nonsignificant trend toward a reduction in the composite end point of death, reinfarction, and disabling stroke (13.7 versus 15.7 percent), which was due to a significant reduction in reinfarction (6.6 versus 10.4 percent).</p><p>The mortality findings are consistent with a community-based sample of 1058 patients, which found that the added benefit from primary PCI increased with overall risk, that 87 percent of the benefit could be attained by treating patients in the upper half of risk, and that, in meta-regression analysis of 10 randomized trials of primary PTCA, a mortality benefit was unlikely in patients with a 30-day mortality risk of about 2 percent or less, which is seen with a TIMI risk score of 0 to 2 (<a href=\"topic.htm?path=calculator-thrombolysis-in-myocardial-infarction-timi-score-for-st-elevation-acute-myocardial-infarction\" class=\"calc calc_professional\">calculator 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/48\" class=\"abstract_t\">48</a>]. The low-risk patients in DANAMI-2 had a 30-day mortality of 2.5 percent with fibrinolysis [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Meta-analysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A large 2009 meta-analysis of randomized controlled trials (RCT) and observational studies (OS), which compared primary PCI (with balloon angioplasty or stenting) to fibrinolysis, came to the following conclusions [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/49\" class=\"abstract_t\">49</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary PCI was associated with significant reductions in short-term (&le;6 weeks) mortality of 34 percent in RCT and 23 percent in OS.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary PCI was associated with significant reductions in long-term (&gt;1 year) mortality of 24 percent and reinfarction of 51 percent in RCT.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No significant benefit of primary PCI compared to fibrinolytic therapy was seen for either mortality or reinfarction in the observational studies.</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Prehospital fibrinolysis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A separate issue is the relative efficacy of primary PCI with stenting and fibrinolysis when the latter can be delivered very early, such as occurs with prehospital fibrinolysis. The role and benefits of prehospital fibrinolysis are discussed in detail separately. (See <a href=\"topic.htm?path=fibrinolysis-for-acute-st-elevation-myocardial-infarction-initiation-of-therapy#H3476241383\" class=\"medical medical_review\">&quot;Fibrinolysis for acute ST elevation myocardial infarction: Initiation of therapy&quot;, section on 'Prehospital fibrinolysis'</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">USE IN SPECIFIC SETTINGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The above trials do not provide data on the efficacy of primary percutaneous coronary intervention (PCI) in a number of specific settings. Mostly nonrandomized data are available for patients with anterior wall myocardial infarction (MI) and prior coronary artery bypass graft surgery (CABG), as well as following noncardiac surgery. The role of primary PCI in cardiogenic shock was evaluated in the randomized SHOCK trial.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Anterior wall MI</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is substantial evidence of benefit of primary PCI for anterior wall in subgroup analyses from randomized trials. As examples, the benefit of primary percutaneous transluminal coronary angioplasty (PTCA) compared to fibrinolysis in PAMI was limited to patients with anterior wall ST elevation myocardial infarction (STEMI) [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/29\" class=\"abstract_t\">29</a>], the benefit of primary stenting compared to fibrinolysis was similar with anterior and nonanterior acute MI in DANAMI-2 [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/37\" class=\"abstract_t\">37</a>], and the benefit of primary stenting compared to primary PTCA was significant with left anterior descending disease, which is responsible for anterior infarctions [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/13\" class=\"abstract_t\">13</a>].</p><p>Efficacy in anterior wall MI was directly addressed in a study in which 220 such patients were randomly assigned to primary PCI or <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">alteplase</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/50\" class=\"abstract_t\">50</a>]. Primary PCI was associated with significant reductions in in-hospital mortality (2.8 versus 10.8 percent), postinfarction angina or positive exercise test (11.9 versus 25.2 percent), repeat revascularization (22 versus 47.7 percent) and, at six months, mortality (4.6 versus 11.7) and revascularization (31.2 versus 55.9 percent).</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Cardiogenic shock</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Observational data from the GUSTO-I trial and the controlled SHOCK trial suggest benefit from an early invasive strategy with revascularization by either PCI or CABG [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/51-53\" class=\"abstract_t\">51-53</a>]. Fibrinolysis is generally not effective for these patients. However it may be of benefit when a significant delay before PCI is anticipated. (See <a href=\"topic.htm?path=prognosis-and-treatment-of-cardiogenic-shock-complicating-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Prior CABG</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There has been an increase in the number of patients presenting with an acute MI who have had a previous CABG. In the National Registry of Myocardial Infarction-2 (NRMI-2), a prior CABG was an independent predictor of mortality (odds ratio 1.23) [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/54\" class=\"abstract_t\">54</a>]. There was no difference in outcome between reperfusion therapy with primary PTCA or a fibrinolytic agent. However, higher-risk patients were more likely to be referred for primary PTCA.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Acute saphenous vein graft occlusion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although uncommon, an acute MI may result from acute saphenous vein graft occlusion. There is little high-quality evidence upon which to recommend either fibrinolysis or primary PCI over the other. In those patients who undergo PCI with stenting, drug-eluting stents (DES) have not been shown to be better than bare metal stents (BMS) in preventing restenosis. (See <a href=\"topic.htm?path=coronary-artery-bypass-graft-surgery-prevention-and-management-of-vein-graft-stenosis\" class=\"medical medical_review\">&quot;Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Elderly patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no trials that specifically compare primary PCI with fibrinolysis in older adults. The available data from subset analyses of major trials and nonrandomized retrospective analyses support a benefit from primary PCI. (See <a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Overview of the acute management of ST-elevation myocardial infarction&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Diabetic patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The limited data available on the effect of diabetes on the outcome after primary PCI suggest that the relative benefit compared to fibrinolytic therapy may be similar to nondiabetics. However, diabetics remain at increased risk, perhaps due in part to microvascular disease. (See <a href=\"topic.htm?path=treatment-of-acute-myocardial-infarction-in-diabetes-mellitus#H7\" class=\"medical medical_review\">&quot;Treatment of acute myocardial infarction in diabetes mellitus&quot;, section on 'Primary PCI'</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Women</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Women tend to be at higher risk with an acute MI than men because they are usually older and have more comorbidities. Nevertheless, women with an STEMI have improved outcomes with primary PCI compared to fibrinolysis and the degree of benefit may actually be greater than in men. These issues are discussed elsewhere. (See <a href=\"topic.htm?path=management-of-coronary-heart-disease-in-women#H13\" class=\"medical medical_review\">&quot;Management of coronary heart disease in women&quot;, section on 'Primary PCI'</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">PCI WHEN FIBRINOLYSIS IS CONTRAINDICATED</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As many as 20 to 30 percent of patients presenting with an acute ST elevation myocardial infarction (STEMI), particularly older adults, are not candidates for fibrinolytic therapy (<a href=\"image.htm?imageKey=CARD%2F68784\" class=\"graphic graphic_table graphicRef68784 \">table 3</a>). (See <a href=\"topic.htm?path=fibrinolysis-for-acute-st-elevation-myocardial-infarction-initiation-of-therapy#H1171216482\" class=\"medical medical_review\">&quot;Fibrinolysis for acute ST elevation myocardial infarction: Initiation of therapy&quot;, section on 'Contraindications'</a>.)</p><p>Patients with contraindications to fibrinolysis represent a high-risk group with an estimated baseline short-term mortality risk of 15 to 25 percent [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/55-58\" class=\"abstract_t\">55-58</a>]. In such patients, immediate percutaneous coronary intervention (PCI) appears to improve outcomes [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/55,56,58-60\" class=\"abstract_t\">55,56,58-60</a>] as well as to salvage a substantial amount of ischemic myocardium [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/59\" class=\"abstract_t\">59</a>].</p><p>The magnitude of benefit is illustrated by the following observations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a nonrandomized study of patients in the National Registry of Myocardial Infarction 2, 3, and 4, over 19,000 patients were identified who had contraindications to fibrinolysis but were suitable candidates for PCI or coronary artery bypass graft surgery (CABG); revascularization was performed in 4705 (24 percent) [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/56\" class=\"abstract_t\">56</a>]. In an analysis using a propensity matching score to reduce the effects of bias, 3905 patients who received revascularization were matched with 3905 patients who did not. The in-hospital mortality was significantly lower for the revascularized patients (10.9 versus 20.1 percent). A significant treatment benefit persisted (odds ratio 0.64, 95% CI 0.56-0.75) after adjustment for residual differences between the two groups.</p><p/><p>A similar benefit was suggested in the synthesis of randomized trials cited above [<a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/55\" class=\"abstract_t\">55</a>]. The absolute reduction in mortality with PCI in patients with contraindications to fibrinolysis was 9.3 percent (95% CI 5.3-13.2 percent).</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reperfusion with either primary percutaneous coronary intervention (PCI) or fibrinolysis improves outcomes in patients with acute ST elevation myocardial infarction (STEMI) or an MI with new or presumably new left bundle branch block or a true posterior MI. For most patients, clinical trials have demonstrated superiority of primary PCI, irrespective of whether balloon angioplasty or stenting is performed. In addition, fibrinolysis is absolutely or relatively contraindicated in many STEMI patients. (See <a href=\"#H3\" class=\"local\">'Primary PCI versus fibrinolytic trials'</a> above and <a href=\"#H19\" class=\"local\">'PCI when fibrinolysis is contraindicated'</a> above.)</p><p>Some patients, such as those who do not have access to prompt PCI, are candidates for fibrinolytic therapy. The discussion of the factors that determine which strategy should be chosen is found elsewhere. (See <a href=\"topic.htm?path=acute-st-elevation-myocardial-infarction-selecting-a-reperfusion-strategy\" class=\"medical medical_review\">&quot;Acute ST elevation myocardial infarction: Selecting a reperfusion strategy&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/1\" class=\"nounderline abstract_t\">Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/2\" class=\"nounderline abstract_t\">Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270:1211.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/3\" class=\"nounderline abstract_t\">Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/4\" class=\"nounderline abstract_t\">GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329:673.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/5\" class=\"nounderline abstract_t\">GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329:1615.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/6\" class=\"nounderline abstract_t\">Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/7\" class=\"nounderline abstract_t\">Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91:1923.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/8\" class=\"nounderline abstract_t\">Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97:1549.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/9\" class=\"nounderline abstract_t\">Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21:1391.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/10\" class=\"nounderline abstract_t\">Karagounis L, Sorensen SG, Menlove RL, et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. J Am Coll Cardiol 1992; 19:1.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/11\" class=\"nounderline abstract_t\">Anderson JL, Karagounis LA, Becker LC, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87:1829.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/12\" class=\"nounderline abstract_t\">Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1739.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/13\" class=\"nounderline abstract_t\">Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/14\" class=\"nounderline abstract_t\">Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/15\" class=\"nounderline abstract_t\">Langer A, Krucoff MW, Klootwijk P, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998; 31:783.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/16\" class=\"nounderline abstract_t\">Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317:581.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/17\" class=\"nounderline abstract_t\">Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990; 82:781.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/18\" class=\"nounderline abstract_t\">Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104:1229.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/19\" class=\"nounderline abstract_t\">Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003; 42:7.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/20\" class=\"nounderline abstract_t\">D&ouml;nges K, Schiele R, Gitt A, et al. Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]). Am J Cardiol 2001; 87:1039.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/21\" class=\"nounderline abstract_t\">Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92:2811.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/22\" class=\"nounderline abstract_t\">Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med 1998; 129:597.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/23\" class=\"nounderline abstract_t\">Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000; 31:1802.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/24\" class=\"nounderline abstract_t\">Cannon CP, Bahit MC, Haugland JM, et al. Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Crit Pathw Cardiol 2002; 1:44.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/25\" class=\"nounderline abstract_t\">Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328:673.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/26\" class=\"nounderline abstract_t\">Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336:1621.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/27\" class=\"nounderline abstract_t\">Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997; 278:2093.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/28\" class=\"nounderline abstract_t\">Nunn CM, O'Neill WW, Rothbaum D, et al. Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol 1999; 33:640.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/29\" class=\"nounderline abstract_t\">Stone GW, Grines CL, Browne KF, et al. Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy. Am J Cardiol 1996; 78:19.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/30\" class=\"nounderline abstract_t\">Saito S, Hosokawa FG, Kim K, et al. Primary stent implantation without coumadin in acute myocardial infarction. J Am Coll Cardiol 1996; 28:74.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/31\" class=\"nounderline abstract_t\">Bauters C, Lablanche JM, Van Belle E, et al. Effects of coronary stenting on restenosis and occlusion after angioplasty of the culprit vessel in patients with recent myocardial infarction. Circulation 1997; 96:2854.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/32\" class=\"nounderline abstract_t\">Stone GW, Brodie BR, Griffin JJ, et al. Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation 1999; 99:1548.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/33\" class=\"nounderline abstract_t\">Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341:1949.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/34\" class=\"nounderline abstract_t\">Suryapranata H, van 't Hof AW, Hoorntje JC, et al. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 1998; 97:2502.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/35\" class=\"nounderline abstract_t\">Antoniucci D, Santoro GM, Bolognese L, et al. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998; 31:1234.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/36\" class=\"nounderline abstract_t\">Nordmann AJ, Bucher H, Hengstler P, et al. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Cochrane Database Syst Rev 2005; :CD005313.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/37\" class=\"nounderline abstract_t\">Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349:733.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/38\" class=\"nounderline abstract_t\">Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation 2005; 112:2017.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/39\" class=\"nounderline abstract_t\">Busk M, Maeng M, Rasmussen K, et al. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. Eur Heart J 2008; 29:1259.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/40\" class=\"nounderline abstract_t\">Widimsk&yacute; P, Budes&iacute;nsk&yacute; T, Vor&aacute;c D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J 2003; 24:94.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/41\" class=\"nounderline abstract_t\">Widimsky P, Bilkova D, Penicka M, et al. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 Trial. Eur Heart J 2007; 28:679.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/42\" class=\"nounderline abstract_t\">Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001; 37:985.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/43\" class=\"nounderline abstract_t\">Sch&ouml;mig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 2000; 343:385.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/44\" class=\"nounderline abstract_t\">Kastrati A, Mehilli J, Dirschinger J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet 2002; 359:920.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/45\" class=\"nounderline abstract_t\">Grines CL, Westerhausen DR Jr, Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002; 39:1713.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/46\" class=\"nounderline abstract_t\">Nielsen PH, Maeng M, Busk M, et al. Primary angioplasty versus fibrinolysis in acute myocardial infarction: long-term follow-up in the Danish acute myocardial infarction 2 trial. Circulation 2010; 121:1484.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/47\" class=\"nounderline abstract_t\">Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102:2031.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/48\" class=\"nounderline abstract_t\">Kent DM, Schmid CH, Lau J, Selker HP. Is primary angioplasty for some as good as primary angioplasty for all? J Gen Intern Med 2002; 17:887.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/49\" class=\"nounderline abstract_t\">Huynh T, Perron S, O'Loughlin J, et al. Comparison of primary percutaneous coronary intervention and fibrinolytic therapy in ST-segment-elevation myocardial infarction: bayesian hierarchical meta-analyses of randomized controlled trials and observational studies. Circulation 2009; 119:3101.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/50\" class=\"nounderline abstract_t\">Garc&iacute;a E, El&iacute;zaga J, P&eacute;rez-Castellano N, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol 1999; 33:605.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/51\" class=\"nounderline abstract_t\">Berger PB, Holmes DR Jr, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation 1997; 96:122.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/52\" class=\"nounderline abstract_t\">Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/53\" class=\"nounderline abstract_t\">Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285:190.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/54\" class=\"nounderline abstract_t\">Peterson LR, Chandra NC, French WJ, et al. Reperfusion therapy in patients with acute myocardial infarction and prior coronary artery bypass graft surgery (National Registry of Myocardial Infarction-2). Am J Cardiol 1999; 84:1287.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/55\" class=\"nounderline abstract_t\">Massel D. Primary angioplasty in acute myocardial infarction: Hypothetical estimate of superiority over aspirin or untreated controls. Am J Med 2005; 118:113.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/56\" class=\"nounderline abstract_t\">Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003; 290:1891.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/57\" class=\"nounderline abstract_t\">Behar S, Gottlieb S, Hod H, et al. The outcome of patients with acute myocardial infarction ineligible for thrombolytic therapy. Israeli Thrombolytic Survey Group. Am J Med 1996; 101:184.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/58\" class=\"nounderline abstract_t\">Zahn R, Schuster S, Schiele R, et al. Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy. Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. Catheter Cardiovasc Interv 1999; 46:127.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/59\" class=\"nounderline abstract_t\">Kastrati A, Mehilli J, Nekolla S, et al. A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. J Am Coll Cardiol 2004; 43:734.</a></li><li><a href=\"https://www.uptodate.com/contents/primary-percutaneous-coronary-intervention-versus-fibrinolysis-in-acute-st-elevation-myocardial-infarction-clinical-trials/abstract/60\" class=\"nounderline abstract_t\">Svilaas T, Zijlstra F. The benefit of an invasive approach in thrombolysis-ineligible patients with acute myocardial infarction. Am J Med 2005; 118:123.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 73 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">LIMITATIONS OF FIBRINOLYSIS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PRIMARY PCI VERSUS FIBRINOLYTIC TRIALS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Primary PCI with balloon angioplasty versus fibrinolysis</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Primary PCI with stenting versus primary PCI with balloon angioplasty</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Meta-analysis</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">Primary PCI with stenting versus fibrinolysis</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">- High- versus low-risk patients</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">Meta-analysis</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Prehospital fibrinolysis</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">USE IN SPECIFIC SETTINGS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Anterior wall MI</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Cardiogenic shock</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Prior CABG</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Acute saphenous vein graft occlusion</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Elderly patients</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Diabetic patients</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Women</a></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">PCI WHEN FIBRINOLYSIS IS CONTRAINDICATED</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/73|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/53374\" class=\"graphic graphic_figure\">- Mortality and time to reperfusion in MI</a></li><li><a href=\"image.htm?imageKey=CARD/75629\" class=\"graphic graphic_figure\">- Mortality after thrombolysis based on TIMI flow </a></li><li><a href=\"image.htm?imageKey=CARD/70952\" class=\"graphic graphic_figure\">- TIMI flow and survival after thrombolysis</a></li><li><a href=\"image.htm?imageKey=CARD/78134\" class=\"graphic graphic_figure\">- TIMI risk score predicts 30-day mortality after STEMI</a></li></ul></li><li><div id=\"CARD/73|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=CARD/51941\" class=\"graphic graphic_table\">- TIMI flow grades</a></li><li><a href=\"image.htm?imageKey=CARD/62946\" class=\"graphic graphic_table\">- Risk factors for intracranial hemorrhage with thrombolysis</a></li><li><a href=\"image.htm?imageKey=CARD/68784\" class=\"graphic graphic_table\">- Contraindications to fibrinolytic therapy</a></li></ul></li></ul></div></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-thrombolysis-in-myocardial-infarction-timi-score-for-st-elevation-acute-myocardial-infarction\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for ST elevation acute myocardial infarction</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-st-elevation-myocardial-infarction-selecting-a-reperfusion-strategy\" class=\"medical medical_review\">Acute ST elevation myocardial infarction: Selecting a reperfusion strategy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiplatelet-agents-in-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Antiplatelet agents in acute ST elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=characteristics-of-fibrinolytic-thrombolytic-agents-and-clinical-trials-in-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-angiography-and-revascularization-for-unstable-angina-or-non-st-elevation-acute-myocardial-infarction\" class=\"medical medical_review\">Coronary angiography and revascularization for unstable angina or non-ST elevation acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-artery-bypass-graft-surgery-prevention-and-management-of-vein-graft-stenosis\" class=\"medical medical_review\">Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fibrinolysis-for-acute-st-elevation-myocardial-infarction-initiation-of-therapy\" class=\"medical medical_review\">Fibrinolysis for acute ST elevation myocardial infarction: Initiation of therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fibrinolytic-thrombolytic-agents-in-acute-st-elevation-myocardial-infarction-markers-of-efficacy\" class=\"medical medical_review\">Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-coronary-heart-disease-in-women\" class=\"medical medical_review\">Management of coronary heart disease in women</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-failed-fibrinolysis-thrombolysis-or-threatened-reocclusion-in-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Overview of the acute management of ST-elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=percutaneous-coronary-intervention-after-fibrinolysis-for-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-percutaneous-coronary-intervention-in-acute-st-elevation-myocardial-infarction-determinants-of-outcome\" class=\"medical medical_review\">Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-percutaneous-coronary-intervention-in-acute-st-elevation-myocardial-infarction-periprocedural-management\" class=\"medical medical_review\">Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prognosis-and-treatment-of-cardiogenic-shock-complicating-acute-myocardial-infarction\" class=\"medical medical_review\">Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-stratification-after-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Risk stratification after acute ST-elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-acute-myocardial-infarction-in-diabetes-mellitus\" class=\"medical medical_review\">Treatment of acute myocardial infarction in diabetes mellitus</a></li></ul></div></div>","javascript":null}